New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY From The Last 14 Days
Check below for free stories on SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
August 29, 2014
16:40 EDTBBYStocks finish week higher after upbeat U.S. data reported
Subscribe for More Information
11:28 EDTBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: ITMN EXPR DSW ARUN ANF SWHC BIG TSL BBY PSEC
10:00 EDTSNESony volatility at low end of historic range as shares advance
Subscribe for More Information
07:46 EDTSNESony, Samsung to launch smartphones with metal-alloy bodies, DigiTimes says
Subscribe for More Information
07:16 EDTRPRXRepros Therapeutics price target raised to $30 on '305 results at BofA/Merrill
Subscribe for More Information
06:19 EDTSNESprint to carry Sony's next Xperia phone in the U.S., WSJ reports
Subscribe for More Information
August 28, 2014
16:21 EDTRPRXOn The Fly: Closing Wrap
Subscribe for More Information
13:57 EDTKERXKeryx September volatility elevated
Keryx September call option implied volatility is at 107, October is at 79, December is at 71; compared to its 26-week average of 76 according to Track Data, suggesting large September price movement.
12:34 EDTRPRXOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as concern over the Ukraine crisis overshadowed an upward revision to the government's estimate of U.S. economic growth in the second quarter. The major averages began the session in negative territory and picked up downside momentum in early trading, but soon after began to drift off their lows and recapture some of their losses. Volume remains light, as is expected ahead of the upcoming long weekend. ECONOMIC EVENTS: In the U.S., Q2 GDP growth was unexpectedly boosted to 4.2% from the first estimate of 4.0%. Personal consumption rose 2.5% during the second quarter, versus estimates for a 2.4% increase. Initial jobless claims ticked down slightly to 298K in the fourth week of August. Pending home sales index increased 3.3% in July, which was better than the 0.5% month-over-month increase that was expected. In Europe, Ukraine president Poroshenko reportedly accused Russia of a "de facto" invasion and canceled a trip to call an urgent meeting of his security and defense council. COMPANY NEWS: Shares of Visa (V) declined 1% after Raymond James lowered its rating on the credit card giant's stock to Market Perform from Outperform. The Dow component faces a number of headwinds, including tougher negotiating tactics by larger international banks looking to win better deals, lower cross-border volume, and loss of processing revenue in Russia, wrote Raymond James analyst Wayne Johnson. MAJOR MOVERS: Among the notable gainers was Repros Therapeutics (RPRX), which jumped 20% after the first of two identical pivotal studies comparing Androxal to an FDA approved topical gel and placebo achieved superiority in both co-primary endpoints and Piper Jaffray hiked its price target on the stock to $33 from $26. Also higher was Signet Jewelers (SIG), which rose nearly 7% after reporting Q2 results that analysts at Sterne Agee called "impressive." Among the noteworthy losers were a number of retailers who dropped after reporting results from their most recent fiscal quarters. Shares of home goods retailer William-Sonoma (WSM) dropped 11%, jeans maker Guess (GES) fell 9%, and apparel retailer Abercrombie & Fitch (ANF) slipped more than 4%. INDEXES: Near midday, the Dow was down 33.92, or 0.2%, to 17,088.09, the Nasdaq was down 4.52, or 0.1%, to 4,565.11, and the S&P 500 was down 2.04, or 0.1%, to 1,998.08.
12:30 EDTSNENetflix buys flagship series 'The Blacklist' for $2M per episode, Deadline says
Subscribe for More Information
11:57 EDTRPRXRepros next Androxal trial should hit endpoints also, says Brean Capital
Subscribe for More Information
10:25 EDTRPRXHigh option volume stocks
Subscribe for More Information
10:10 EDTRPRXRepros Therapeutics price target raised to $33 from $26 at Piper Jaffray
Subscribe for More Information
08:55 EDTRPRXOn The Fly: Pre-market Movers
HIGHER: Digital Ally (DGLY), up 16% after announcing order from Michigan State Police for over $1.1M... EnteroMedics (ETRM), up 12.4% after reporting three-year data from Maestro RC system... Repros (RPRX), up 0.8% after Androxal achieves superiority in both co-primary endpoints in a study... Synthetic Biologics (SYN), up 2.7% after Pfizer (PFE) was granted FDA Fast Track designation for its investigational Clostridium difficile vaccine candidate. Synthetic Biologics announced earlier this week that SYN-004, the company's lead anti-infective product candidate for the prevention of the effects of C. difficile, will be presented in October... Signet (SIG), up 3.9% after Q2 revenue tops consensus. DOWN AFTER EARNINGS: Abercrombie & Fitch (ANF), down 5.7%... Guess (GES), down 8.3%... Frontline (FRO), down 7%. ALSO LOWER: Williams-Sonoma (WSM), down 10.9% after downgraded at Morgan Stanley following the company's Q2 earnings report... GT Advanced (GTAT), down 2% after downgraded at Raymond James... Sungy Mobile (GOMO), down 20.1% following earnings report, CFO resignation, downgrade of stock at Oppenheimer... Genesco (GCO), down 7.7% after cutting fiscal year forecast.
07:29 EDTRPRXRepros Therapeutics to host conference call
Conference call to discuss Androxal's top line results will be held on August 28 at 9 am. Webcast Link
05:10 EDTRPRXRepros reports Androxal achieves superiority in both co-primary endpoints
Subscribe for More Information
August 27, 2014
12:52 EDTBBYBest Buy rebounds after analysts defend stock
Shares of Best Buy (BBY) are advancing after a number of analysts defended the stock in the wake of the weaker than expected guidance that the company provided yesterday. WHAT'S NEW: After Best Buy yesterday morning reported slightly lower than expected second quarter revenue and estimated that its same-store sales would rise by a weaker than expected low single digit percentage in the second half of 2014, Piper Jaffray analyst Peter Keith said the results were solid while the guidance looks conservative. Best Buy's consumer electronics sales rose for the first time in several years last quarter and its U.S. comparative sales numbers were "decent," while its online sales surged 22%, Keith noted. Best Buy's sales guidance looks conservative because the retailer should benefit from the launch of Apple's (AAPL) iPhone 6 next month, while its TV sales, which are rebounding, historically become a larger part of its total sales in Q3 and Q4, the analyst wrote. He reiterated a $34 price target and Overweight rating on the shares. Meanwhile, Deutsche Bank wrote that Best Buy is significantly cutting its costs, as the firm had predicted. It believes that the retailer can reduce its costs meaningfully going forward and it kept a $33 price target and Buy rating on the stock. PRICE ACTION: In early afternoon trading, Best Buy advanced $1.49, or 5%, to $31.29. Yesterday, the stock fell nearly 7% following the company's quarterly report, which was issued before the opening bell.
11:49 EDTBBYBest Buy rallies on heavy volume, levels to watch
Volume is already running at more than 150% of the daily average, with the shares up 5.4% to $31.41. The move has nearly filled the bearish gap from yesterday, the top of which is at $31.99. That level remains resistance. Positive commentary from Piper Jaffray and Deutsche Bank this morning have helped spur the rally. Support is at $30.95.
10:36 EDTBBYOptions with decreasing implied volatility
Subscribe for More Information
09:26 EDTROPCressey & Company, Level Equity sell Strategic Healthcare Programs to Roper
Subscribe for More Information
07:02 EDTBBYBest Buy can cut costs further, says Deutsche Bank
Subscribe for More Information
06:56 EDTBBYBest Buy 2H14 guidance looks conservative, says Piper Jaffray
Subscribe for More Information
August 26, 2014
16:34 EDTROPRoper Industries announces two medical acquisitions
Roper Industries announced that it has acquired Strategic Healthcare Programs, or SHP, and Innovative Product Achievements, or IPA. Both companies will become part of Roper's Medical and Scientific Imaging segment. SHP, headquartered in Santa Barbara, CA, is a leading provider of software and informatics solutions to the post-acute healthcare market. IPA, headquartered in Suwanee, GA, is the leading manufacturer of automated surgical scrub dispensing equipment for acute care hospitals and other healthcare providers. Including the previously announced Foodlink software acquisition, Roper has invested $303M in acquisitions during Q3. The company expects the acquisitions to be accretive to 2015 earnings.
16:22 EDTBBYOn The Fly: Closing Wrap
Subscribe for More Information
15:24 EDTBBYBest Buy valuation compelling, says BofA/Merrill
14:58 EDTBBYBest Buy still poised to beat Q4 expectations, says Jefferies
After Best Buy reported lower than expected Q2 revenue, Jefferies still expects the company to rebound in 2H14, with Q4 results beating expectations. The firm expects the company to benefit from positive product cycle trends in 2H14 and says that its Q2 sales were in-line with its expectations. Jefferies keeps a $38 price target and Buy rating on the shares.
14:54 EDTBBYBest Buy risk/reward favorable, says Credit Suisse
Credit Suisse remains a buyer of Best Buy and said risk/reward is favorable. The firm was not surprised by negative comps and lower earnings forecasts for the rest of the year and believes the company is poised to report Q4 upside. Shares are Outperform rated with a $40 price target.
14:47 EDTBBYBest Buy shares defended at Jefferies
Subscribe for More Information
14:17 EDTBBYInvestors should sell Best Buy, Barron's reports
Subscribe for More Information
12:24 EDTBBYOn The Fly: Midday Wrap
Subscribe for More Information
11:23 EDTBBYTRW September volatility elevated
Subscribe for More Information
11:12 EDTRPRX, BBYHigh option volume stocks
Subscribe for More Information
11:09 EDTBBYBest Buy shares decline as Best Buy reports Q2 sales drop
Shares of multi-channel Best Buy (BBY) are retreating after the firm reported that sales declines continued through the second quarter. WHAT'S NEW: Best Buy's Q2 earnings per share from continuing operations was 44c, exceeding analysts' consensus estimates of 31c. The company's Q2 revenue was $8.9B, which was slightly lower than analysts' $8.99B consensus. Same-store-sales for the quarter declined 2.7%, which is better than the overall industry sales decline of 2.5% as reported by NPD. Best Buy Chief Executive Officer Hubert Joly noted that traffic to the company's brick and mortar stores continued to decline as consumers research and buy online. Joly noted that in-store conversion and online traffic continued to increase during the quarter. Joly said that in the back half of the year, the retailer plans to intensify its investments in customer-facing initiatives. Chief Financial Officer and Chief Administrative Officer Sharon McCollam reiterated that industry-wide sales are continuing to decline in many of the consumer electronics cateogries in which it competes, and said the retailer is seeing "ongoing softness" in the mobile phone category ahead of new product launches. She forecast SSS down in the low single digits for both the third and fourth quarters and sees Q3 and Q4 operating income in line with the first half of the year. For the back half of the year, McCollam sees continued industry softness and higher promotionality in Canada and China. WHAT'S NOTABLE: During the company's conference call, Best Buy said that it is "encouraged" by the response to 4K televisions and aims to expand its holiday gift centers within stores. The company's CFO McCollam said that the firm's mobile phone category is "complicated to forecast." She feels that the disruption of carriers "could have impact" that the technology retailer did not anticipate. McCollam said that despite great excitement for some high-profile phone launches, there is still a great deal of competition in the lower-end of the phone market. In terms of the start of the upcoming quarter, Best Buy feels that the beginning has been "in-line" with expectations. ANALYST OPINION: ISI analyst Greg Melich feels that Best Buy's Q2 EPS beat was due to a slightly less dramatic decrease in gross margins and improved cost controls. He feels that the market is likely to pay close attention to continued sales decreases when predicting the rest of the year despite the better than anticipated quarterly EPS results. Melich said that he will keep an eye out for positive signs that Q4 will experience an improvement given the highly promotional and competitive landscape last year. The analyst keeps the stock with a neutral rating and a $31.99 price target. PRICE ACTION: In morning trading, Best Buy fell $1.59, or 4.97%, to $30.40. OTHERS TO WATCH: Best Buy peers include RadioShack (RSH) and hhgregg (HGG).
11:01 EDTBBYBest Buy shares defended at Morgan Stanley
09:01 EDTSNEElectronic Arts launches Madden NFL 15 on Xbox One, PS4
Subscribe for More Information
08:56 EDTBBYOn The Fly: Pre-market Movers
HIGHER: Tim Hortons (THI), up 10.5% after announcing merger agreement with Burger King (BKW), which is up 4% after the news. Burger King CEO Schwartz will become group CEO of the new company and Berkshire Hathaway (BRK.A) has committed $3B of preferred equity financing for the deal... DSW (DSW), up 12% after reporting Q2 earnings beat, FY14 outlook above consensus... Kite Pharma (KITE), up 17% after announcing phase 1-2a results from trial of potential treatment of non-Hodgkin's lymphoma... Mobileye (MBLY), up 4.4% after coverage of stock initiated at several research firms, including Morgan Stanley which started with an Overweight rating and $46 price target and named it a new top pick... Kandi Technologies (KNDI), up 9% following Bloomberg report on Chinese government considering funding for electric car chargers. LOWER: Best Buy (BBY), down 3.7% after reporting Q2 revenue below consensus, Q2 same-store sales decline of 2.7%... Sanderson Farms (SAFM), down 5.9% after Q3 earnings, revenue miss estimates... Movado (MOV), down 5.1% after Q2 revenue miss expectations... DOWN AFTER EARNINGS: Prospect Capital (PSEC), down 3.5%... Trina Solar (TSL), down 7.6%.
08:54 EDTBBYBest Buy CEO says beginning of quarter has been 'in-line with expectations'
Subscribe for More Information
08:44 EDTBBYBest Buy CFO says mobile phone category 'complicated to forecast'
Subscribe for More Information
08:18 EDTBBYBest Buy CEO says 'encouraged' by response to 4K televisions
Subscribe for More Information
07:10 EDTBBYBest Buy sees Q3, Q4 operating income rate up in line with 1H
Subscribe for More Information
07:04 EDTBBYBest Buy sees ongoing softness in mobile phone category
Subscribe for More Information
07:03 EDTBBYBest Buy CFO sees SSS down in low single digits in Q3, Q4
Subscribe for More Information
07:02 EDTBBYBest Buy: Benefits of Renew Blue cost reduction drove Q2 results
Subscribe for More Information
07:01 EDTBBYBest Buy reports Q2 continuing ops EPS 44c, consensus 31c
Subscribe for More Information
August 25, 2014
15:18 EDTBBYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Best Buy (BBY), consensus 31c; Golar LNG (GLNG), consensus (7c); DSW (DSW), consensus 32c; Tech Data (TECD), consensus 77c; Sanderson Farms (SAFM), consensus $3.82; Movado (MOV), consensus 54c; Trina Solar (TSL), consensus 14c.
14:14 EDTBBYBest Buy technical comments ahead of results
Subscribe for More Information
10:24 EDTBBYBest Buy weekly volatility increases into Q2 and outlook
Subscribe for More Information
06:44 EDTSNESony's PSN back online following cyber attack
Subscribe for More Information
06:04 EDTSNEAmerican Airlines flight diverted as Sony exec receives threat, Re/code reports
Subscribe for More Information
August 24, 2014
16:34 EDTSNESony says PlayStation impacted by Denial of Service attack
Subscribe for More Information
August 22, 2014
11:59 EDTSNEGameStop surges after Q2 EPS, revenue beat expectations
Subscribe for More Information
11:05 EDTRPRXPiper Jaffray biopharm analyst holds an analyst/industry conference call
Subscribe for More Information
09:01 EDTRPRXRepros Therapeutics has favorable near-term catalysts, says BofA/Merrill
BofA/Merrill lowered Repros Therapeutics' price target to $27 from $32 due to competitive pricing and a contraction in the TRT market but says it expects favorable near-term data from Androxal and AndroGel studies. The firm expects the Sept 17 FDA meeting to access DV risks from exogenous testosterone to be favorable. Shares are Buy rated.
06:37 EDTBBYBest Buy weekly volatility elevated into Q2 and outlook
Subscribe for More Information
August 20, 2014
10:39 EDTCATCaterpillar data may be negative for shares in short-term, says Wells Fargo
Subscribe for More Information
10:35 EDTCATCaterpillar reported world Machines sales down 9%
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use